Skip to main content
Premium Trial:

Request an Annual Quote

FDA Buys Toxicology Data Mining Software, Databases from LeadScope

NEW YORK, Nov. 9 — LeadScope has sold its Enterprise data mining software and ToxScope toxicity databases to the US Food and Drug Administration to help the agency perform in silico  toxicology assessments.  

Under the agreement, which is an extension of a deal struck earlier in the year, the FDA will be able to use both the public toxicity information, which is provided in the ToxScope toxicity databases, together with its own data to “identify relationships between chemical structures and toxicity,” LeadScope said in a statement.

Financial terms of the sale were not disclosed.

“The FDA expects to use LeadScope in its safety assessment of food contact materials,” an FDA spokesman added. “We expect the software to be particularly useful in resolving safety questions concerning the potential mutagenicity of food contact substances.”

Earlier this year, LeadScope, of Columbus, Ohio, had collaborated with the FDA under a material transfer agreement that provides the agency with limited access to the LeadScope technology. This agreement was with the Center for Drug Evaluation and Research and the Center for Food Safety and Applied Nutrition.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.